Min He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Min He has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Liang Hong
Joint Laboratory of Chinese Herbal Glycoengineering and Testing Technology, University of Macau & National Glycoengineering Research Center, Macau 999078, China
10 shared publications Yaping Li
Department of Quality Control, Xiangtan Central Hospital, Xiangtan, Hunan, 411100, China
8 shared publicationsPan Yan
Department of Pharmaceutical Engineering, School of Chemical Engineering, Xiangtan University, Xiangtan, 411105, People's Republic of China
6 shared publicationsJun Zeng
Department of Pharmaceutical Engineering, School of Chemical Engineering, Xiangtan University, Xiangtan 411105, China
5 shared publicationsTian-Biao Yang
5 shared publicationsZhi-Yu Yang
5 shared publications
Latest Publications
- 30 September 2026
- Published by Wiley in Flavour and Fragrance Journal
Bio‐Guided Oral Microencapsulation of Curcuma wenyujin Essential Oils via Complex Coacervation: Structural Preservation and Preliminary Evidence of Intestinal Distribution
This study developed a chitosan‐sodium alginate complex coacervation microencapsulation system to stabilize and orally deliver Curcuma wenyujin essential oil (WYJY). Chemical profiling via GC–MS and MCR‐ALS deconvolution revealed that both steam distillation (SD) and supercritical CO 2 extraction (SCE) effectively yielded bioactive sesquiterpenoids, with SCE uniquely co‐extracting non‐volatile endogenous lipids and sterols. Network pharmacology combined with in vitro assays in HK‐2 cells validated that these major sesquiterpenoids possess robust anti‐inflammatory bioactivities by significantly suppressing IL‐6 and TNF‐α expressions. Based on this biological relevance and the instability of WYJY, the multi‐component essential oil was directly utilized as a unified core to fabricate regular core‐shell microcapsules. Multidimensional spectroscopic and thermal analyses (TG/DTG/DSC) verified that sequestration within the dense polymer matrix drastically enhanced the thermal stability of the volatile core. Furthermore, in vitro and in vivo evaluations demonstrated that this system exhibited good biocompatibility and an enteric release profile. HS‐SPME‐GC–MS tracking in rats at 1 h after oral administration detected characteristic WYJY terpenoid markers in rinsed intestinal tissues and serum, suggesting intestinal distribution and possible systemic exposure. Overall, this work provides a practical strategy for the chemical preservation, structural stabilization, and intestinal delivery of sensitive essential oils from medicinal plants.
- 30 September 2026
- Published by Wiley in Flavour and Fragrance Journal
Bio‐Guided Oral Microencapsulation of Curcuma wenyujin Essential Oils via Complex Coacervation: Structural Preservation and Preliminary Evidence of Intestinal Distribution
This study developed a chitosan‐sodium alginate complex coacervation microencapsulation system to stabilize and orally deliver Curcuma wenyujin essential oil (WYJY). Chemical profiling via GC–MS and MCR‐ALS deconvolution revealed that both steam distillation (SD) and supercritical CO 2 extraction (SCE) effectively yielded bioactive sesquiterpenoids, with SCE uniquely co‐extracting non‐volatile endogenous lipids and sterols. Network pharmacology combined with in vitro assays in HK‐2 cells validated that these major sesquiterpenoids possess robust anti‐inflammatory bioactivities by significantly suppressing IL‐6 and TNF‐α expressions. Based on this biological relevance and the instability of WYJY, the multi‐component essential oil was directly utilized as a unified core to fabricate regular core‐shell microcapsules. Multidimensional spectroscopic and thermal analyses (TG/DTG/DSC) verified that sequestration within the dense polymer matrix drastically enhanced the thermal stability of the volatile core. Furthermore, in vitro and in vivo evaluations demonstrated that this system exhibited good biocompatibility and an enteric release profile. HS‐SPME‐GC–MS tracking in rats at 1 h after oral administration detected characteristic WYJY terpenoid markers in rinsed intestinal tissues and serum, suggesting intestinal distribution and possible systemic exposure. Overall, this work provides a practical strategy for the chemical preservation, structural stabilization, and intestinal delivery of sensitive essential oils from medicinal plants.
- Top Cited PapersOpen Access
- 23 March 2026
- Published by Elsevier in Journal of Advanced Research
AI-driven multi-scale target analysis of traditional Chinese medicine: From the pharmacological effects of single compounds to the synergistic mechanisms of formulae
- 23 March 2026
- Published by Elsevier in Journal of Advanced Research
Top Cited PapersOpen AccessAI-driven multi-scale target analysis of traditional Chinese medicine: From the pharmacological effects of single compounds to the synergistic mechanisms of formulae
- 27 April 2024
- Published by Springer Nature
- p. 837-881
Chemometrics in Quality Control of Traditional Chinese Medicines
- 27 April 2024
- Published by Springer Nature
- p. 837-881
Chemometrics in Quality Control of Traditional Chinese Medicines
- Open Access
- 21 January 2024
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 14 (4) , 100936
Analysis of GC × GC fingerprints from medicinal materials using a novel contour detection algorithm: A case of Curcuma wenyujin
- 21 January 2024
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 14 (4) , 100936
Open AccessAnalysis of GC × GC fingerprints from medicinal materials using a novel contour detection algorithm: A case of Curcuma wenyujin
- 21 July 2022
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1238, 340189
Image classification combined with faster R–CNN for the peak detection of complex components and their metabolites in untargeted LC-HRMS data
- 21 July 2022
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1238, 340189
Image classification combined with faster R–CNN for the peak detection of complex components and their metabolites in untargeted LC-HRMS data
- Open Access
- 7 July 2022
- Published by Springer Nature in Chinese Medicine
- Vol. 17 (1) , 1-13
Predicting for anti-(mutant) SARS-CoV-2 and anti-inflammation compounds of Lianhua Qingwen Capsules in treating COVID-19
Background: Lianhua Qingwen Capsules (LHQW) is a traditional Chinese medicine prescription commonly used to treat viral influenza in China. There has been sufficient evidence that LHQW could effectively treat COVID-19. Nevertheless, the potential anti-(mutant) SARS-CoV-2 and anti-inflammation compounds in LHQW are still vague.Methods: The compounds of LHQW and targets were collected from TCMSP, TCMID, Shanghai Institute of Organic Chemistry of CAS database, and relevant literature. Autodock Vina was used to carry out molecular docking. The pkCSM platform to predict the relevant parameters of compound absorption in vivo. The protein–protein interaction (PPI) network was constructed by the STRING database. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was carried out by Database for Annotation, Visualization, and Integrated Discovery (DAVID). The anti-(mutant) SARS-CoV-2 and anti-inflammation networks were constructed on the Cytoscape platform.Results: 280 compounds, 16 targets related to SARS-CoV-2, and 54 targets related to cytokine storm were obtained by screening. The key pathways Toll-like receptor signaling, NOD-like receptor signal pathway, and Jak-STAT signaling pathway, and the core targets IL6 were obtained by PPI network and KEGG pathway enrichment analysis. The network analysis predicted and discussed the 16 main anti-SARS-CoV-2 active compounds and 12 main anti-inflammation active compounds. Ochnaflavone and Hypericin are potential anti-mutant virus compounds in LHQW.Conclusions: In summary, this study explored the potential anti-(mutant) SARS-CoV-2 and anti-inflammation compounds of LHQW against COVID-19, which can provide new ideas and valuable references for discovering active compounds in the treatment of COVID-19.
- 7 July 2022
- Published by Springer Nature in Chinese Medicine
- Vol. 17 (1) , 1-13
Open AccessPredicting for anti-(mutant) SARS-CoV-2 and anti-inflammation compounds of Lianhua Qingwen Capsules in treating COVID-19
Background: Lianhua Qingwen Capsules (LHQW) is a traditional Chinese medicine prescription commonly used to treat viral influenza in China. There has been sufficient evidence that LHQW could effectively treat COVID-19. Nevertheless, the potential anti-(mutant) SARS-CoV-2 and anti-inflammation compounds in LHQW are still vague.Methods: The compounds of LHQW and targets were collected from TCMSP, TCMID, Shanghai Institute of Organic Chemistry of CAS database, and relevant literature. Autodock Vina was used to carry out molecular docking. The pkCSM platform to predict the relevant parameters of compound absorption in vivo. The protein–protein interaction (PPI) network was constructed by the STRING database. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was carried out by Database for Annotation, Visualization, and Integrated Discovery (DAVID). The anti-(mutant) SARS-CoV-2 and anti-inflammation networks were constructed on the Cytoscape platform.Results: 280 compounds, 16 targets related to SARS-CoV-2, and 54 targets related to cytokine storm were obtained by screening. The key pathways Toll-like receptor signaling, NOD-like receptor signal pathway, and Jak-STAT signaling pathway, and the core targets IL6 were obtained by PPI network and KEGG pathway enrichment analysis. The network analysis predicted and discussed the 16 main anti-SARS-CoV-2 active compounds and 12 main anti-inflammation active compounds. Ochnaflavone and Hypericin are potential anti-mutant virus compounds in LHQW.Conclusions: In summary, this study explored the potential anti-(mutant) SARS-CoV-2 and anti-inflammation compounds of LHQW against COVID-19, which can provide new ideas and valuable references for discovering active compounds in the treatment of COVID-19.